Aktis Oncology, Inc. Common stockEigentümerstruktur
| Preis (2026-07-27) | 52W Hoch | 52W Tief |
| 24.21 USD | 34,19 USD | 14,72 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 2,95 USD | 2 | 1 | 2 | 0 | 0 |
| #Shares | Short [%] | Short Ratio |
| 53.404.618 | 23,64 | 5,92 |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Aktis Oncology, Inc. Common stock
Mitarbeiter 79
Handelsplatz NASDAQ
Ticker Symbol AKTS
IPO Datum 2026-01-09
Adresse 17 Drydock Avenue, Boston, MA, United States, 02210
Webseite https://www.aktisoncology.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. Todd Foley M.B.A. | Co-Founder & Chairman |
| 2 | Dr. Matthew Roden Ph.D. | President, CEO & Director |
| 3 | Dr. Paul L. Feldman Ph.D. | Chief Scientific Officer |
| 4 | Dr. Akos Czibere M.D., Ph.D. | Chief Medical Officer |
| 5 | Dr. Patrick A. Baeuerle Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| 6 | Mr. Kyle D. Kuvalanka | Chief Financial Officer |
| 7 | Dr. Shulamit Ron-Bigger Ph.D. | Chief Operating Officer |
| 8 | Dr. Tyler Benedum Ph.D. | Chief Technical Officer |
| 9 | Mr. Carlos Rodriguez | Executive Director of Corporate Development |
| 10 | Dr. Dasa Lipovsek Ph.D. | VP & Head of Lead Discovery |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
| Rang | Inhaber | Anteile | Wert |
|---|---|---|---|
| 1 | MPM Oncology Impact Management LP | 0,00% | 0,00 Mio. USD |
| 2 | EcoR1 Capital, LLC | 0,00% | 0,00 Mio. USD |
| 3 | Blue Owl Capital Holdings LP | 0,00% | 0,00 Mio. USD |
| 4 | Wellington Management Company LLP | 0,00% | 0,00 Mio. USD |
| 5 | T. Rowe Price Investment Management,Inc. | 0,00% | 0,00 Mio. USD |
| 6 | BlackRock Inc | 0,00% | 0,00 Mio. USD |
| 7 | RTW INVESTMENTS, LLC | 0,00% | 0,00 Mio. USD |
| 8 | T. Rowe Price Associates, Inc. | 0,00% | 0,00 Mio. USD |
| 9 | RA Capital Management, LLC | 0,00% | 0,00 Mio. USD |
| 10 | HHG PLC | 0,00% | 0,00 Mio. USD |
| 11 | Baker Bros Advisors LP | 0,00% | 0,00 Mio. USD |
| 12 | Octagon Capital Advisors LP | 0,00% | 0,00 Mio. USD |
| 13 | Merck & Co Inc | 0,00% | 0,00 Mio. USD |
| 14 | Avidity Partners Management LP | 0,00% | 0,00 Mio. USD |
| 15 | Vanguard Capital Management, LLC | 0,00% | 0,00 Mio. USD |
| 16 | Eventide Asset Management, LLC | 0,00% | 0,00 Mio. USD |
| 17 | Geode Capital Management, LLC | 0,00% | 0,00 Mio. USD |
| 18 | State Street Corp | 0,00% | 0,00 Mio. USD |
| 19 | FMR Inc | 0,00% | 0,00 Mio. USD |
| 20 | UBS Group AG | 0,00% | 0,00 Mio. USD |